These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 29597186)
1. Levels of Endocan, Angiopoietin-2, and Hypoxia-Inducible Factor-1a in Patients with Autosomal Dominant Polycystic Kidney Disease and Different Levels of Renal Function. Raptis V; Bakogiannis C; Loutradis C; Boutou AK; Lampropoulou I; Intzevidou E; Sioulis A; Balaskas E; Sarafidis PA Am J Nephrol; 2018; 47(4):231-238. PubMed ID: 29597186 [TBL] [Abstract][Full Text] [Related]
2. Serum Fas Ligand, Serum Myostatin and Urine TGF-β1 Are Elevated in Autosomal Dominant Polycystic Kidney Disease Patients with Impaired and Preserved Renal Function. Raptis V; Bakogiannis C; Loutradis C; Boutou AK; Sioulis A; Balaskas E; Zebekakis P; Sarafidis PA Kidney Blood Press Res; 2018; 43(3):744-754. PubMed ID: 29794429 [TBL] [Abstract][Full Text] [Related]
3. Serum Copeptin, NLPR3, and suPAR Levels among Patients with Autosomal-Dominant Polycystic Kidney Disease with and without Impaired Renal Function. Raptis V; Loutradis C; Boutou AK; Faitatzidou D; Sioulis A; Ferro CJ; Papagianni A; Sarafidis PA Cardiorenal Med; 2020; 10(6):440-451. PubMed ID: 33202410 [TBL] [Abstract][Full Text] [Related]
4. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease. Coban M; Inci A Int Urol Nephrol; 2018 Jul; 50(7):1293-1300. PubMed ID: 29654395 [TBL] [Abstract][Full Text] [Related]
5. Elevated asymmetric dimethylarginine is associated with oxidant stress aggravation in patients with early stage autosomal dominant polycystic kidney disease. Raptis V; Georgianos PI; Sarafidis PA; Sioulis A; Makedou K; Makedou A; Grekas DM; Kapoulas S Kidney Blood Press Res; 2013; 38(1):72-82. PubMed ID: 24577239 [TBL] [Abstract][Full Text] [Related]
6. Hypoxia and Endothelial Dysfunction in Autosomal-Dominant Polycystic Kidney Disease. Theodorakopoulou M; Raptis V; Loutradis C; Sarafidis P Semin Nephrol; 2019 Nov; 39(6):599-612. PubMed ID: 31836042 [TBL] [Abstract][Full Text] [Related]
15. Kidney Function Reserve Capacity in Early and Later Stage Autosomal Dominant Polycystic Kidney Disease. Messchendorp AL; van Londen M; Taylor JM; de Borst MH; Navis G; Casteleijn NF; Gaillard CAJM; Bakker SJL; Gansevoort RT; Clin J Am Soc Nephrol; 2018 Nov; 13(11):1680-1692. PubMed ID: 30254028 [TBL] [Abstract][Full Text] [Related]
16. The association of endothelin-1 levels with renal survival in polycystic kidney disease patients. Kocyigit I; Eroglu E; Kaynar AS; Kocer D; Kargi S; Zararsiz G; Bayramov R; Imamoglu H; Sipahioglu MH; Tokgoz B; Dundar M; Oymak O J Nephrol; 2019 Feb; 32(1):83-91. PubMed ID: 30022320 [TBL] [Abstract][Full Text] [Related]
17. Copeptin levels and kidney function in ADPKD: case-control study. Corradi V; Martino F; Gastaldon F; Scalzotto E; Caprara C; Fortunato A; Pinaffo G; Marchetti C; Fabbi F; Giavarina D; Ferrari F; Rosner MH; Ronco C Clin Nephrol; 2016 Sep; 86(9):147-53. PubMed ID: 27487355 [TBL] [Abstract][Full Text] [Related]
18. Endothelial Dysfunction and Atherosclerosis in Patients With Autosomal Dominant Polycystic Kidney Disease. Ekinci İ; Buyukkaba M; Cinar A; Tunc M; Cebeci E; Gursu M; Kazancioglu R Cureus; 2021 Feb; 13(2):e13561. PubMed ID: 33815976 [TBL] [Abstract][Full Text] [Related]
19. Urinary biomarkers at early ADPKD disease stage. Petzold K; Poster D; Krauer F; Spanaus K; Andreisek G; Nguyen-Kim TD; Pavik I; Ho TA; Serra AL; Rotar L PLoS One; 2015; 10(4):e0123555. PubMed ID: 25875363 [TBL] [Abstract][Full Text] [Related]
20. Uroflowmetry alterations in patients with autosomal dominant polycystic kidney disease. Lai S; Mittherhofer AP; Cianci R; Riviello L; Vocaturi M; Mastroluca D; Ciccariello M; Von Heland M; Ricciuti GP; Salciccia S; Mazzaferro S Eur Rev Med Pharmacol Sci; 2019 Apr; 23(7):2734-2743. PubMed ID: 31002123 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]